Determinants of adherence to non-occupational post HIV exposure prophylaxis

AIDS

Volumn 20, Issue 2, 2006, Pages 291-294

  Lacombe, Karine ^a,b   Daguenel Nguyen, Anne ^a   Lebeau, Véronique ^a   Fonquernie, Laurent ^a   Girard, Pierre Marie ^a,b   Meyohas, Marie Caroline ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; CHEMOPROPHYLAXIS; DIARRHEA; FATIGUE; FEMALE; FRANCE; GEOGRAPHIC ORIGIN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL SEXUAL CONTACT; PATIENT COMPLIANCE; POSTEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RASH;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; SEXUAL BEHAVIOR;

EID: 33646027608     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000199832.10478.83     Document Type: Article

References (11)

1. Stephenson J. PEP talk: treating nonoccupational HIV exposure. JAMA 2003; 289:287-288.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
3. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-1490.
4. Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JSG, O'Shaughnessy MV, Hogg RS. Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme. AIDS 2001; 15:2345-2347.
5. Sociales MdlSedA. Circular DGS/DH/DRT/DSS no. 98/228 of 9 April about recommendations for the implementation of antiretroviral treatment after exposure to the risk of transmission of HIV [in French]. Paris, France: Assistance Publique Hopitaux de Paris; 1998.
6. Lot F, Larsen C, Basselier B, Laporte A. Evaluation of the therapeutic assumption of responsibility for exposures to HIV; July 1999-December 2001 [in French]. BEH 2003; 36:173-175.
7. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46-54.
8. Sonder GJB, Regez RM, Brinkman K, Prins JM, Mulder JW, Spaargaren J, et al. Prophylaxis and follow-up after possible exposure to HIV, hepatitis B virus, and hepatitis C virus outside hospital: evaluation of policy 2000-3. BMJ 2005; 330:825-829.
9. Schlechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to post-exposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-525.
10. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
11. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, Karstaedt AS. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004; 20:1053-1056.